FDA approves lower dose of Symjepi for the emergency treatment of allergic reactions, including anaphylaxis.- Admis Pharma
Adamis Pharmaceuticals Corporation announced that the FDA has approved Adamis� lower dose version (0.15mg) of Symjepi for the emergency treatment of allergic reactionSymjepis (Type I) including anaphylaxis. Symjepi (epinephrine) Injection 0.3mg is an FDA-approved product, for the emergency treatment of allergic reactions (Type I) including anaphylaxis, designed for patients weighing 66 pounds or greater. The lower dose version (0.15mg) is intended to potentially treat patients weighing 33-66 pounds.
Both Symjepi products will provide two single-dose injections syringes of epinephrine (adrenaline), which is considered the drug of choice for immediate administration in acute anaphylactic reactions to allergic reaction to foods (such as nuts), insect stings or bites, drugs and other allergens, as well as idiopathic or exercise-induced anaphylaxis.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins